Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialBrian G. Feagan, Rupert W. Leong, Julián Panés et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 235
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin‐Biroulet, Toshimitsu Fujii, Jessica R. Allegretti et al.|Gastroenterology|2023Cited by 97
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T. Rubin, Patrick Chamouard, Jessica R. Allegretti et al.|The Lancet|2024Cited by 95
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority TrialWolfgang Kruis, Roland Greinwald, Britta Siegmund et al.|Journal of Crohn s and Colitis|2022Cited by 15